Journal of biochemistry
A kinase inhibitor screen identifies GSK690693 as a Hippo pathway inhibitor targeting ER-positive breast cancer.
Haruka Kurata, Samson Ngurari, Akihiro Nita, Yasuhisa Sakamoto, David Nduru, Toshiro Moroishi
Published: 202610.1093/jb/mvag005
Abstract
The Hippo pathway, traditionally recognized for its tumor suppressive function, has been paradoxically implicated in promoting tumor progression in cancers such as estrogen receptor-positive breast cancer. Treatment of ER-positive breast cancer faces…
Preview only. Read the full abstract at the source